EA for Protracted Withdrawal of OUD

July 10, 2021 updated by: Ren Yu-Lan, Chengdu University of Traditional Chinese Medicine

Electrical Acupuncture for Protracted Withdrawal of Opioid Use Disorder: A Pragmatic Randomized Controlled Trial

Opioid use disorder (OUD) the most harmful of all the illicit drugs is a serious substance-related disorder resulting from abuse or misuse of opioids. Huge number of patients are addictive to opioid and evidences show that patients with OUD have high rates of infectious diseases.The "World Drug Report 2020" has declared that 58 million people used opioids in 2018 and some 35.6 million people suffered from drug use disorders globally. More than 11 million people inject drugs, while 1.4 million PWID are living with HIV, 5.5 million with hepatitis C and 1.2 million are living with both hepatitis C and HIV.

The long-term physical and mental symptoms of some opioid drug users after detoxification treatment are called protracted opioid withdrawal syndrome (POAS). POAS is one of the important causes of relapse. Methadone maintenance treatment is the most widespread and extensively researched treatment for heroin addiction and has been shown to reduce the frequency of opioid use, the mortality, and the transmission of human immunodeficiency virus and viral hepatitis. But higher daily methadone dose and increasing duration of treatment conduce the addiction in methadone. Other medication therapy like naltrexone treatment is also associated with high rates of noncompliance and opioid relapse. Meanwhile, relapse to heroin use following cessation of agonist maintenance treatment is common. The problems associated with use of opioid agonists have made it necessary to develop non-opioid therapies to ameliorate the symptoms of acute and protracted opioid withdrawal.

Acupuncture based on traditional Chinese medicine (TCM) theory is becoming a popular complementary and alternative treatment worldwide. Study showed that acupuncture reduced the depression symptoms and cravings of patients under methadone maintenance treatment. Another study by Le et al. (2016) showed that electric acupuncture has been associated with a reduction in depressive symptoms through the adjustment of HPA axis function and increasing the hippocampus activity. And also some research show the efficiency of acupuncture in treating mice with OUD.

Investigators conduct a pragmatic randomized controlled trials(pRCT) to observe the effect of acupuncture in a larger sample. It combines the advantages of randomization and real-world data, and the results can provide the best real-world evidence for the assessment of intervention effects or comparative effects.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Sichuan
      • Chengdu, Sichuan, China, 610072
        • Recruiting
        • Affliated Hospital of Chengdu University of Traditional Chinese Medicine
        • Contact:
          • Binbin Wu, Doctor
          • Phone Number: 0086-18190061169
          • Email: 9025340@qq.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • meet the diagnostic criteria
  • the results of detection of morphine in urine is negative
  • the patients must be conscious, with no aphasia, no intellectual disability, and graduate from primary school so they can understand what the scale mean and cooperate the treatment.
  • not involved in any clinical trials in 3 months
  • sign the Informed Consent Form

Exclusion Criteria:

  • with any injury or infection around the acupoint
  • the patients are intolerant or allergic to acupuncture or electro-acupuncture
  • the women is pregnant or lactating
  • patients whose heart, liver or kidney with severe impairment
  • according to the judgement from investigators, patients don't correspond with this research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Electro-Acupuncture group
The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
Device: Electro-Acupuncture
Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
No Intervention: Wait-list group
We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opiate Withdrawal Syndrome Scale
Time Frame: Change from baseline Opiate Withdrawal Syndrome Scale scores at 1 month.
It consists of three subscales, namely, "anxiety and mood", "fatigue", and "craving". Items are scored on a five-point scale ranging from 0 to 4 with higher scores representing more severe PAAS.
Change from baseline Opiate Withdrawal Syndrome Scale scores at 1 month.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hamilton Depression Scale (HAMD)
Time Frame: Change from baseline Hamilton Depression Scale scores at 1 month.
Assessment for depression.And the interpretation of HAMD scores is as follows: <7, no depression; 7-17, mild depression; 17-24, moderate depression; and >24, severe depression.
Change from baseline Hamilton Depression Scale scores at 1 month.
Hamilton Anxiety Scale (HAMA)
Time Frame: Change from baseline Hamilton Anxiety Scale scores at 1 month.
Assessment for anxiety. And the interpretation of HAMA scores is as follows: <7, no anxiety;7-14, mild anxiety; 14-20, moderate anxiety; 21-28, severe anxiety; and >29, extremely severe anxiety.
Change from baseline Hamilton Anxiety Scale scores at 1 month.
Pittsburgh sleep quality index (PSQI)
Time Frame: Change from baseline Pittsburgh sleep quality index scores at 1 month.
The scores are from 0 to 21.Higher scores reflect worse sleep quality.
Change from baseline Pittsburgh sleep quality index scores at 1 month.
Concise health survey questionnaire
Time Frame: Change from baseline Concise health survey questionnaire scores at 1 month.All scores were recoded with 0 as a minimum score and 100 as a maximum score; a higher score indicates a better quality of life.
This questionnaire contains 9 parts: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health and Reported Health Transition.
Change from baseline Concise health survey questionnaire scores at 1 month.All scores were recoded with 0 as a minimum score and 100 as a maximum score; a higher score indicates a better quality of life.
Dopamine (DA)
Time Frame: baseline and one month
The physiological parameter to observe the efficiency of acupuncture.
baseline and one month
5-hydroxytryptamine (5-HT)
Time Frame: Change from baseline 5-hydroxytryptamine at 1 month.
The physiological parameter to observe the efficiency of acupuncture.
Change from baseline 5-hydroxytryptamine at 1 month.
Liver function
Time Frame: Change from baseline alanine aminotransferase, aspartate aminotransferase, bilirubin total and direct bilirubin at 1 month.
The physiological parameter to prove the safety of acupuncture.
Change from baseline alanine aminotransferase, aspartate aminotransferase, bilirubin total and direct bilirubin at 1 month.
Renal function
Time Frame: Change from baseline serum creatinine, blood uric acid and blood urea nitrogen at 1 month.
The physiological parameter to prove the safety of acupuncture.
Change from baseline serum creatinine, blood uric acid and blood urea nitrogen at 1 month.
Testosterone
Time Frame: Change from baseline Testosterone at 1 month.
The physiological parameter to observe the efficiency of acupuncture.
Change from baseline Testosterone at 1 month.
Prolactin (PRL)
Time Frame: Change from baseline Prolactin at 1 month.
The physiological parameter to observe the efficiency of acupuncture.
Change from baseline Prolactin at 1 month.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chengdu University of Traditional Chinese Medicine

Investigators

  • Study Chair: Yulan Ren, PhD, Chengdu University of Traditional Chinese Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

July 1, 2021

Primary Completion (Anticipated)

July 1, 2022

Study Completion (Anticipated)

December 1, 2023

Study Registration Dates

First Submitted

May 26, 2021

First Submitted That Met QC Criteria

July 10, 2021

First Posted (Actual)

July 14, 2021

Study Record Updates

Last Update Posted (Actual)

July 14, 2021

Last Update Submitted That Met QC Criteria

July 10, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2018SZ071

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe